Albemarle Corporation $ALB Shares Sold by Algert Global LLC

Algert Global LLC decreased its position in Albemarle Corporation (NYSE:ALB) by 32.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 197,817 shares of the specialty chemicals company’s stock after selling 95,186 shares during the quarter. Algert Global LLC owned 0.17% of Albemarle worth $16,039,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. BOKF NA grew its stake in shares of Albemarle by 5,771.4% in the third quarter. BOKF NA now owns 411 shares of the specialty chemicals company’s stock valued at $33,000 after buying an additional 404 shares in the last quarter. Cromwell Holdings LLC boosted its holdings in Albemarle by 36.8% during the 3rd quarter. Cromwell Holdings LLC now owns 413 shares of the specialty chemicals company’s stock valued at $34,000 after acquiring an additional 111 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in Albemarle by 536.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 573 shares of the specialty chemicals company’s stock valued at $36,000 after acquiring an additional 483 shares during the period. Physician Wealth Advisors Inc. acquired a new position in Albemarle in the 3rd quarter valued at about $40,000. Finally, Hantz Financial Services Inc. increased its stake in Albemarle by 70.4% during the third quarter. Hantz Financial Services Inc. now owns 692 shares of the specialty chemicals company’s stock worth $56,000 after purchasing an additional 286 shares during the period. 92.87% of the stock is currently owned by hedge funds and other institutional investors.

Key Albemarle News

Here are the key news stories impacting Albemarle this week:

• Positive Sentiment: Company confirmed a quarterly dividend of $0.405 per share (ex-dividend March 13), supporting income-focused demand and signaling confidence in cash flow. Albemarle Declares Quarterly Dividend
• Positive Sentiment: Board refresh and strategic moves: Albemarle added two finance executives to the board, launched up to $500M of debt tender offers, redeemed 2027 notes and announced a planned sale of a controlling interest in its Ketjen business — actions that can improve capital structure and focus the portfolio. Board refresh, Ketjen sale and debt moves
• Positive Sentiment: Several sell-side analysts remain constructive or raised targets (UBS, Jefferies, Argus), leaving an overall “Moderate Buy” consensus and supporting upside potential if lithium demand recovers. MarketBeat analyst summary
• Neutral Sentiment: Zacks pieces note mixed short-term moves (e.g., ALB was up ~3.1% since the last earnings report in one write-up) and provide context rather than new fundamental news — useful for sentiment but not a direct catalyst. Why Is Albemarle Up 3.1% Since Last Earnings?
• Negative Sentiment: CEO J. Kent Masters sold 11,783 shares (~$2.0M) on March 10, reducing his stake ~8% — insider selling often spooks investors and can add near-term downward pressure. Insider sale filing
• Negative Sentiment: Recent quarterly results (Feb. 11) showed an EPS miss (‑$0.53 vs. est. ‑$0.40) despite revenue beating; negative net margin and continued quarterly losses keep near-term profitability under scrutiny. Earnings and financials summary
• Negative Sentiment: Zacks and MarketBeat noted the stock has declined more than the broader market in recent sessions, reflecting the combined effect of the earnings miss, insider selling and broader commodity/EV cycle sentiment. ALB sees dip vs. market

Insider Buying and Selling

In related news, CEO J Kent Masters sold 11,783 shares of the stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $170.81, for a total transaction of $2,012,654.23. Following the completion of the sale, the chief executive officer owned 134,628 shares in the company, valued at $22,995,808.68. This represents a 8.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.33% of the stock is currently owned by company insiders.

Albemarle Stock Down 3.6%

Shares of NYSE ALB opened at $158.00 on Friday. The business has a 50-day moving average price of $170.89 and a 200 day moving average price of $128.66. The stock has a market cap of $18.59 billion, a PE ratio of -27.48, a price-to-earnings-growth ratio of 1.21 and a beta of 1.43. The company has a quick ratio of 1.57, a current ratio of 2.23 and a debt-to-equity ratio of 0.41. Albemarle Corporation has a 52-week low of $49.43 and a 52-week high of $206.00.

Albemarle (NYSE:ALB) last released its quarterly earnings results on Wednesday, February 11th. The specialty chemicals company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.13). Albemarle had a positive return on equity of 0.41% and a negative net margin of 10.74%.The firm had revenue of $1.43 billion for the quarter, compared to analyst estimates of $1.34 billion. During the same period last year, the firm earned ($1.09) EPS. The company’s quarterly revenue was up 15.9% on a year-over-year basis. Equities research analysts forecast that Albemarle Corporation will post -0.04 earnings per share for the current year.

Albemarle Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Stockholders of record on Friday, March 13th will be issued a $0.405 dividend. This represents a $1.62 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Friday, March 13th. Albemarle’s payout ratio is presently -28.17%.

Analyst Ratings Changes

Several analysts have recently issued reports on ALB shares. Robert W. Baird set a $210.00 price target on shares of Albemarle and gave the stock an “outperform” rating in a research report on Wednesday, January 7th. BMO Capital Markets increased their target price on shares of Albemarle from $145.00 to $210.00 and gave the stock an “outperform” rating in a report on Tuesday, January 20th. HSBC raised shares of Albemarle from a “hold” rating to a “buy” rating and set a $200.00 price target for the company in a research report on Monday, January 19th. Wells Fargo & Company set a $165.00 price target on shares of Albemarle in a research note on Monday, February 16th. Finally, Mizuho upped their price objective on Albemarle from $156.00 to $185.00 and gave the stock a “neutral” rating in a research report on Thursday, February 12th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $170.24.

Albemarle Profile

Albemarle Corporation is a leading global specialty chemicals company primarily engaged in the production and distribution of lithium, bromine, and catalysts. Its lithium segment supplies key components used in rechargeable batteries for electric vehicles, portable electronics, and grid storage systems. The company’s bromine specialty products serve a wide range of industries, including oil and gas drilling fluids, fire safety solutions, and water treatment. In its catalysts division, Albemarle provides products for petroleum refining, chemical processing and emissions control.

Founded in 1994 as a spin-off from Ethyl Corporation, Albemarle has grown through strategic acquisitions and capacity expansions to become one of the world’s foremost chemical producers.